Takeda says IgGNITE Phase 2/3 trial shows TAK-881 matches HyQvia pharmacokinetics in PID patients 16+

By Public Technologies
  • Takeda presented detailed Phase 2/3 IgGNITE results for investigational subcutaneous TAK-881 in primary immunodeficiency disease at ESID 2026.
  • The study met its primary endpoint, supporting comparability to Takeda’s marketed HYQVIA in patients aged 16 and older.
  • Descriptive findings indicated similar infection protection, safety, and tolerability to HYQVIA, with no new safety signals.
  • TAK-881 could reduce administration burden versus HYQVIA, with shorter infusions and fewer infusion sites enabled by lower volume dosing.
  • Regulatory submissions in the US, EU, and Japan are planned in fiscal 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Takeda Pharmaceutical Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610140800BIZWIRE_USPR_____20261014_BW178348) on October 14, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.